RxDoctor Payments Data

Alexander Roka

Family Medicine · San Antonio, TXNPI 1982602264

Payments from drug & device makers

$21,342in general payments, 2019–2025

Across 1,373 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Lilly USA, LLC$2K
  • Novo Nordisk$2K
  • GSK$1K
  • Amgen$1K
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$21,323100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)235$2,959
AstraZeneca113$2,381
Lilly USA, LLC154$2,102
Novo Nordisk112$1,754
GSK96$1,442
Amgen(2 entities)92$1,203
Pfizer84$949
Bayer43$816
Antares Pharma, Inc.51$728
Johnson & Johnson35$627
Amarin Pharma, Inc.28$521
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC33$488
Boehringer Ingelheim22$446
Teva Pharmaceuticals USA, Inc.14$381
Kowa Pharmaceuticals America, Inc.21$362
Esperion Therapeutics, Inc.23$333
Takeda Pharmaceuticals U.S.A., Inc.22$315
Merck24$303
Revance Therapeutics, Inc.3$259
Abbott11$235
Idorsia Pharmaceuticals US Inc10$194
Sanofi-aventis U.S. LLC9$154
Bausch Health US, LLC9$139
Novartis7$111
Eisai Inc.7$109
Ardelyx, Inc.5$102
Otsuka America Pharmaceutical, Inc.4$88
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$78
Astellas Pharma US Inc5$77
Corcept Therapeutics3$77
Dexcom, Inc.3$75
Nalpropion Pharmaceuticals LLC5$70
Gilead4$69
Genentech USA, Inc.4$68
Axsome Therapeutics, Inc.3$67
Azurity Pharmaceuticals, Inc.4$64
Phathom Pharmaceuticals, Inc.3$57
Althera Pharmaceuticals LLC5$55
Biotronik Inc.1$55
Ironwood Pharmaceuticals, Inc3$53
Exact Sciences3$52
Mannkind Corporation3$51
Ironshore Pharmaceuticals Inc.3$51
Acerus Pharmaceuticals Corporation3$47
Tolmar, Inc.3$46
Medtronic(2 entities)3$46
Alk-abello, Inc2$44
Supernus Pharmaceuticals, Inc.2$43
Aytu Biopharma, Inc.2$41
Inspire Medical Systems, Inc.2$34
Arbor Pharmaceuticals, Inc.2$32
Sumitomo Pharma America, Inc.2$31
Upsher-smith Laboratories LLC2$31
Halozyme Inc2$30
Scilex Pharmaceuticals Inc.2$30
Currax Pharmaceuticals LLC2$28
Adlon Therapeutics L.p.2$25
Radius Health, Inc.1$24
Corium, LLC1$23
Almatica Pharma LLC1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,342 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$437,219
Medicare patients
628
Services billed
3,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide183$225,332
MounjaroTirzepatide91$102,676
FarxigaDapagliflozin Propanediol78$76,226
EliquisApixaban50$47,909
TrulicityDulaglutide40$45,231
JardianceEmpagliflozin35$42,993
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$41,405
MyrbetriqMirabegron32$23,575
JanuviaSitagliptin Phosphate11$15,528
LinzessLinaclotide15$14,817
Tresiba Flextouch U-100Insulin Degludec19$13,932
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$12,503
Xigduo XrDapaglifloz Propaned/Metformin11$12,046
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$9,022
Rosuvastatin Calcium519$8,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,754$225,332183 claims
Lilly USA, LLCMounjaro, Trulicity$2,102$147,908131 claims
AstraZenecaFarxiga$2,381$76,22678 claims
PfizerEliquis$949$47,90950 claims
Boehringer IngelheimJardiance$446$42,99335 claims
GSKTrelegy Ellipta$1,442$41,40559 claims
Astellas Pharma US IncMyrbetriq$77$23,57532 claims
AbbVieLinzess, Synthroid$2,959$17,54347 claims
MerckJanuvia$303$15,52811 claims
Kowa Pharmaceuticals America, Inc.Livalo$362$7,96414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →